This is the first study that establishes the role of MALT1-LPCAT3 axis in the development of osteoarthritis and provides novel therapeutic avenues targeting this pathway using LPCAT3 siRNA-lipid nanoparticle approach or local injections of MALT1-inhibitors for the treatment of OA. Here, LPCAT3 is linked to osteoarthritis.